

Product Update:

rilpivirine 25mg film-coated tablet (Edurant[®])
Janssen-Cilag Ltd

SMC No. (1168/16)

08 July 2016

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

rilpivirine (Edurant[®]) is accepted for use within NHS Scotland.

Indication under review: in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) \leq 100,000 HIV-1 RNA copies/mL.

The Scottish Medicines Consortium has previously accepted rilpivirine in this indication in adult patients.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including June 2016.

**Chairman,
Scottish Medicines Consortium**